Microbot Medical Inc

Microbot Medical Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)6.92
  • Today's Change-0.05 / -0.72%
  • Shares traded5.23k
  • 1 Year change-6.11%
  • Beta4.5415
Data delayed at least 15 minutes, as of Sep 16 2021 21:00 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms are comprised of ViRob, TipCAT and Liberty, including certain CardioSert assets. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. TipCAT is a disposable self-propelled locomotive device, designed to advance in tubular anatomies. Liberty is a disposable robotic system, designed to move guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.01m
  • Incorporated1988
  • Employees12.00
  • Location
    Microbot Medical Inc25 RECREATION PARK DR SUITE 108HINGHAM 02043United StatesUSA
  • Phone+1 (908) 938-5561
  • Fax+1 (302) 655-5049
  • Websitehttp://www.microbotmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Virios Therapeutics LLC0.00-16.56m46.73m3.00--2.04-----1.90-1.900.002.740.00----0.00-132.32---148.68-------------89.260.00-------318.27------
NanoViricides Inc0.00-8.62m46.94m17.00--1.47-----0.858-0.8580.002.770.00----0.00-34.99-39.68-37.33-45.48-----------70.710.0052-------59.61---73.62--
Navidea Biopharmaceuticals Inc872.43k-11.95m47.05m13.00--8.24--53.94-0.4377-0.43770.03180.18920.0949--0.27167,110.00-123.60-105.66-259.57--99.9998.21-1,302.50-618.752.45-3,621.850.00--39.10-41.41-4.02--44.33--
Greenlink International Inc1.32m-1.00m47.92m10.00------36.34-0.0031-0.00310.0041-0.0071.1940.4128.46---90.30-70.66----0.424719.02-76.05-26.760.0653-8.92-----30.19-12.0224.15------
Forte Biosciences Inc0.00-20.29m48.08m10.00--0.9634-----1.61-1.610.003.540.00----0.00-49.98-72.22-54.27-90.79-------1,273.90----0.00---100.00--26.81------
Rapid Therapeutic Science Laborators Inc2.05k-2.56m48.39m----122.02--23,602.67-0.0143-0.01430.000010.0020.00270.0105-----333.55------49.76---124,652.70--0.1027-47.660.5307--------------
BioCardia Inc195.00k-13.29m48.59m24.00--3.10--249.18-0.9135-0.91350.01310.9290.0117--0.88048,125.00-79.73-97.01-109.63-118.6282.568.68-6,816.92-2,616.10----0.00---79.58-30.65-2.01------
Windtree Therapeutics Inc0.00-62.82m48.60m31.00--0.8562-----2.91-2.910.002.130.00----0.00-57.32-41.97-62.19-51.71-------2,512.43---1,616.850.2218---100.00---18.53---8.67--
Nugenerex Immuno-Oncology Inc0.00-6.29m49.15m6.00---------0.0291-0.02910.00--0.00----0.00-244.01-----------------5.43---------43.39------
Microbot Medical Inc0.00-10.01m49.19m12.00--2.44-----1.41-1.410.002.830.00----0.00-38.66-57.64-40.26-68.96-----------101.120.00-------26.52--114.59--
Universe Pharmaceuticals Inc38.61m9.63m49.37m227.004.050.9744.901.280.56040.56042.082.330.8214.253.48170,079.5020.48--28.26--45.49--24.95--3.43174.210.1037---7.60--0.0894------
Trinity Biotech plc (ADR)116.22m-1.51m49.75m543.00----31.650.428-0.072-0.095.56-0.02060.91711.877.17214,025.80-1.19-13.81-2.41-15.5246.7943.74-1.30-27.480.44273.731.01--12.770.353879.26---17.44--
Cell Source Inc0.00-6.32m49.97m-----------0.2082-0.20820.00-0.30110.00-------2,773.37-1,209.56---------------2.87---------4.22------
Skye Bioscience Inc0.00-6.98m49.99m6.00--20.89-----0.0218-0.02180.000.00570.00----0.00-244.37-390.82-694.15-------------9.510.4236-------723.74--29.57--
Baudax Bio Inc543.00k-37.60m51.06m57.00------94.03-0.3967-0.39670.0116-0.05430.00731.151.819,526.32-50.37---65.21---358.38---6,924.13--2.87-27.122.31-------133.74------
Acorda Therapeutics Inc151.90m-132.02m52.17m167.00--0.2735--0.3435-15.34-15.3410.9217.150.24911.5910.55909,562.90-21.65-10.88-26.04-12.2969.5278.62-86.91-31.141.29-1.540.475---20.50-20.8663.51---9.08--
Data as of Sep 16 2021. Currency figures normalised to Microbot Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

10.15%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2021266.45k3.75%
BlackRock Fund Advisorsas of 30 Jun 2021137.39k1.93%
Contego Capital Group, Inc.as of 30 Jun 2021100.00k1.41%
Dimensional Fund Advisors LPas of 30 Jun 202153.38k0.75%
Geode Capital Management LLCas of 30 Jun 202150.50k0.71%
Renaissance Technologies LLCas of 30 Jun 202140.11k0.56%
SSgA Funds Management, Inc.as of 30 Jun 202134.47k0.49%
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 202115.60k0.22%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202111.88k0.17%
Steward Partners Investment Advisory LLCas of 30 Jun 202111.60k0.16%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.